Research ArticleRheumatoid Arthritis

Can Patients With Controlled Rheumatoid Arthritis Taper Methotrexate From Targeted Therapy and Sustain Remission? A Systematic Review and Metaanalysis

Charis F. Meng, Diviya A. Rajesh, Deanna P. Jannat-Khah, Bridget Jivanelli and Vivian P. Bykerk
The Journal of Rheumatology January 2023, 50 (1) 36-47; DOI: https://doi.org/10.3899/jrheum.220152

REFERENCES

  1. 1.↵
    1. Smolen JS,
    2. Landewé RBM,
    3. Bijlsma JWJ, et al.
    EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685-99.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Choy E,
    2. Aletaha D,
    3. Behrens F, et al.
    Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology 2017;56:689-97.
    OpenUrl
  3. 3.
    1. Emery P,
    2. Sebba A,
    3. Huizinga TWJ.
    Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013;72:1897-904.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Detert J,
    2. Klaus P.
    Biologic monotherapy in the treatment of rheumatoid arthritis. Biologics 2015;9:35-43.
    OpenUrlPubMed
  5. 5.↵
    1. Nikiphorou E,
    2. Negoescu A,
    3. Fitzpatrick JD, et al.
    Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. Clin Rheumatol 2014;33:609-14.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Curtis JR,
    2. Bykerk VP,
    3. Aassi M,
    4. Schiff M.
    Adherence and persistence with methotrexate in rheumatoid arthritis: a systematic review. J Rheumatol 2016;43:1997-2009.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Harley CR,
    2. Frytak JR,
    3. Tandon N.
    Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9:S136-43.
    OpenUrlPubMed
  8. 8.↵
    1. Emery P,
    2. Pope JE,
    3. Kruger K, et al.
    Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: a systematic review. Adv Ther 2018;35:1535-63.
    OpenUrl
  9. 9.
    1. Yamanaka H,
    2. Tanaka Y,
    3. Takeuchi T, et al.
    Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther 2016;18:34.
    OpenUrlPubMed
  10. 10.↵
    1. Fleischmann R,
    2. Takeuchi T,
    3. Schiff M, et al.
    Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate. Arthritis Care Res 2020;72:1112-21.
    OpenUrlPubMed
  11. 11.↵
    1. Shaw Y,
    2. Metes ID,
    3. Michaud K, et al.
    Rheumatoid arthritis patients’ motivations for accepting or resisting disease-modifying antirheumatic drug treatment regimens. Arthritis Care Res 2018;70:533-41.
    OpenUrl
  12. 12.↵
    1. Kuijper TM,
    2. Lamers-Karnebeek FBG,
    3. Jacobs JWG,
    4. Hazes JMW,
    5. Luime JJ.
    Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol 2015; 42:2012-22.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Mangoni AA,
    2. Al Okaily F,
    3. Almoallim H,
    4. Al Rashidi S,
    5. Mohammed RHA,
    6. Barbary A.
    Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature. BMC Rheumatol 2019;3:10.
    OpenUrl
  14. 14.↵
    1. Manders SHM,
    2. van de Laar MAFJ,
    3. Rongen-van Dartel SAA, et al.
    Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry. RMD Open 2015;1:e000147.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Kremer JM,
    2. Weinblatt ME,
    3. Bankhurst AD, et al.
    Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003;48:1493-9.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Fraenkel L,
    2. Bathon JM,
    3. England BR, et al.
    2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 2021;73:924-39.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Subesinghe S,
    2. Scott IC.
    Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis. Expert Rev Clin Pharmacol 2015;8:751-60.
    OpenUrl
  18. 18.↵
    1. Tweehuysen L,
    2. van den Ende CH,
    3. Beeren FMM,
    4. Been EMJ,
    5. van den Hoogen FHJ
    6. den Broeder AA.
    Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a biologic agent in rheumatoid arthritis: a systematic review. Arthritis Rheumatol 2017;69:301-8.
    OpenUrl
  19. 19.↵
    1. Liberati A,
    2. Altman DG,
    3. Tetzlaff J, et al.
    The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Emery P,
    2. Breedveld F,
    3. van der Heijde D, et al.
    Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 2010;62:674-82.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Emery P,
    2. Breedveld F,
    3. Pedersen R, et al.
    Relationships between DAS28 response and clinical, functional and radiographic outcomes in year 2 of the COMET study of etanercept in patients with rheumatoid arthritis [abstract]. Arthritis Rheumatol 2019;71:2382.
    OpenUrl
  22. 22.↵
    1. Higgins JPT,
    2. Savovic J,
    3. Page MJ,
    4. Sterne JAC.
    Revised Cochrane risk-of-bias tool for randomized Trials (RoB 2). [Internet. Accessed September 27, 2022.] Available from: https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2
  23. 23.↵
    1. Jonathan AC,
    2. Sterne MAH,
    3. Barnaby C Reeves, et al.
    Current version of ROBINS-I. [Internet. Accessed September 27, 2022.] Available from: https://www.riskofbias.info/welcome/home/current-version-of-robins-i
  24. 24.↵
    1. Ranganathan P,
    2. Aggarwal R,
    3. Pramesh CS.
    Common pitfalls in statistical analysis: Odds versus risk. Perspect Clin Res 2015; 6:222-4.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Tufanaru C,
    2. Munn A,
    3. Stephenson M,
    4. Aromotaris E.
    Common pitfalls in statistical analysis: odds versus risk. Int J Evid Based Healthc 2015;13:196-207.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. von Hipple PT.
    The heterogeneity statistic I(2) can be biased in small meta-analyses. BMC Med Res Methodol 2015;15:35.
    OpenUrlPubMed
  27. 27.↵
    1. Harbord RM,
    2. Egger M,
    3. Sterne JAC.
    A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006;25:3443-57.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Harbord RM,
    2. Harris RJ,
    3. Sterne JAC.
    Updated tests for small-study effects in meta-analyses. Stata J 2009;9:197-210.
    OpenUrlCrossRef
  29. 29.↵
    1. Curtis JR,
    2. Emery P,
    3. Karis E, et al.
    Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission. Arthritis Rheumatol 2021;73:759-68.
    OpenUrlPubMed
  30. 30.↵
    1. Keystone EC,
    2. Pope JE,
    3. Thorne JC, et al.
    Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. Rheumatology 2016;55:327-34.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Pope JE,
    2. Haraoui B,
    3. Thorne JC, et al.
    The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis 2014;73:2144-51.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Pablos JL,
    2. Navarro F,
    3. Blanco FJ, et al.
    Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study. Clin Exp Rheumatol 2019;37:437-44.
    OpenUrl
  33. 33.↵
    1. Kremer JM,
    2. Rigby W,
    3. Singer NG, et al.
    Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized, controlled trial. Arthritis Rheumatol 2018;70:1200-8.
    OpenUrl
  34. 34.↵
    1. Edwards CJ,
    2. Östör AJK,
    3. Naisbett-Groet B, et al.
    Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial. Rheumatology 2018;57:84-91.
    OpenUrlPubMed
  35. 35.↵
    1. Cohen S,
    2. Pope J,
    3. Haraoui B, et al.
    Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. The Lancet Rheumatology, 2019;1:e23-34.
    OpenUrl
  36. 36.↵
    1. Yamaoka K,
    2. Cohen SB,
    3. Sugiyama N, et al.
    Predictors of durable clinical response to tofacitinib 11 mg once daily with or without methotrexate in patients with rheumatoid arthritis: post hoc analysis of data from a phase 3b/4 methotrexate withdrawal study [abstract]. Arthritis Rheumatol 2020;72:0200.
    OpenUrl
  37. 37.↵
    1. Pope J,
    2. Rampakakis E,
    3. Vaillancourt J, et al.
    An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs. Rheumatology 2020;59:1522-8.
    OpenUrlPubMed
  38. 38.↵
    1. Keystone EC,
    2. Breedveld FC,
    3. Kupper H,
    4. Li Y,
    5. Florentinus S,
    6. Sainsbury I.
    Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis. RMD Open 2018;4:e000637.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Emery P,
    2. Tanaka Y,
    3. Bykerk V, et al.
    Maintenance of remission following dose de-escalation of abatacept in early, MTX-naïve, ACPA-positive patients with RA: results from a randomized phase IIIb study [abstract]. Arthritis Rheumatol 2019;71:L11.
    OpenUrl
  40. 40.↵
    1. Emery P,
    2. Tanaka Y,
    3. Bykerk V, et al.
    Maintenance of SDAI remission and patient-reported outcomes (PROs) following dose de-escalation of abatacept in MTX-naïve anti-citrullinated protein antibody (ACPA)+ patients with early RA: results from AVERT-2, a randomised phase IIIB study [abstract]. Ann Rheum Dis 2020;79:985-6.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Fleischmann R,
    2. Mysler E,
    3. Hall S, et al.
    Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 2017;390:457-68.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Smolen JS,
    2. Pangan AL,
    3. Emery P, et al.
    Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019;393:2303-11.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Prince FHM,
    2. Bykerk VP,
    3. Shadick NA, et al.
    Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther 2012;14:R68.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Emery P,
    2. Burmester GR,
    3. Bykerk VP, et al.
    Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 2015;74:19-26.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Vodencarevic A,
    2. Tascilar K,
    3. Hartmann F, et al.
    Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs. Arthritis Res Ther 2021;23:67.
    OpenUrl
  46. 46.↵
    1. Schlager L,
    2. Loiskandl M,
    3. Aletaha D,
    4. Radner H.
    Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Rheumatology 2020;59:324-34.
    OpenUrl
  47. 47.↵
    1. Ghiti Moghadam M,
    2. Vonkeman HE,
    3. Ten Klooster PM, et al.
    Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 2016;68:1810-7.
    OpenUrl
  48. 48.↵
    1. Tanaka Y,
    2. Takeuchi T,
    3. Mimori T, et al.
    Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69:1286-91.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Kuijper TM,
    2. Luime JJ,
    3. de Jong PHP, et al.
    Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial. Ann Rheum Dis 2016;75:2119-23.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

METHOTREXATE
REMISSION
RHEUMATOID ARTHRITIS

Keywords